Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement

Nabe, Yoshimi; Kikuchi, Shohei; Kamihara, Yusuke; Wada, Akinori; Murakami, Jun; Sato, Tsutomu

doi:10.1002/ccr3.4657

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was demonstrated in another case where FCM immunophenotyping of ascitic fluid detected a DHL in a relapsed DLBCL patient [179]. Moreover, evaluating early therapy response via FCM proved valuable in predicting outcome and optimizing the treatment strategy for a patient with primary BM B cell lymphoma [180].…”

Section: Case Studies Using Proteomicsmentioning

confidence: 93%

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Jiménez,

Garrote-de-Barros,

López-Portugués

et al. 2024

IJMS

View full text Add to dashboard Cite

The maturation of B cells is a complex, multi-step process. During B cell differentiation, errors can occur, leading to the emergence of aberrant versions of B cells that, finally, constitute a malignant tumor. These B cell malignancies are classified into three main groups: leukemias, myelomas, and lymphomas, the latter being the most heterogeneous type. Since their discovery, multiple biological studies have been performed to characterize these diseases, aiming to define their specific features and determine potential biomarkers for diagnosis, stratification, and prognosis. The rise of advanced -omics approaches has significantly contributed to this end. Notably, proteomics strategies appear as promising tools to comprehensively profile the final molecular effector of these cells. In this narrative review, we first introduce the main B cell malignancies together with the most relevant proteomics approaches. Then, we describe the core studies conducted in the field and their main findings and, finally, we evaluate the advantages and drawbacks of flow cytometry, mass cytometry, and mass spectrometry for the profiling of human B cell disorders.

show abstract

Section: Case Studies Using Proteomicsmentioning

confidence: 93%

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Jiménez,

Garrote-de-Barros,

López-Portugués

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…7,22,24 R-CHOP chemotherapy has been used with variable success. 7,25,26 In a study by the International Extranodal Lymphoma Study Group (IELSG), the majority of PBM-DLBCL patients received CHOPregimens with or without rituximab with a CR of 33%. Two of the 5 CRs relapsed.…”

Section: Dovepressmentioning

confidence: 99%

Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes

Kimbrough¹,

Jiang²,

Parent³

et al. 2022

JBM

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is well known for selectively involving certain extranodal locations such as the central nervous system (CNS), testes, and skin. DLBCL or high-grade B-cell lymphoma selectively involving the bone marrow is rare and has been sparsely reported in the medical literature. We report two cases of lymphoma presenting with primary bone marrow involvement without evidence of involvement of any other sites. The first case represents de novo DLBCL. The patient achieved complete remission with initial treatment, had a bone marrow-only relapse three years later, and achieved a second complete remission following non-transplant salvage therapy. The second case had findings consistent with "double hit" Richter's transformation of chronic lymphocytic leukemia with translocation of c-MYC and BCL-2. This patient had an aggressive clinical course characterized by rapid progression with CNS involvement within three months resulting in the demise of the patient. These two cases represent two distinct subtypes of primary bone marrow lymphoma: de novo and transformed. Further research is necessary to gain a better understanding of this rare lymphoma entity and develop novel therapies. Keywords: diffuse large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL-2 rearrangements, bone marrow involvement, cytopenias Plain Language Summary• Primary bone marrow lymphoma (PBML) is confined to the bone marrow with or without a leukemic component and represents a distinct, aggressive type of extranodal lymphoma. • PBML is very rare and has been sparsely reported in the medical literature.• PBML appears to consist of two subtypes: de novo PBML and PBML derived from transformation of bone marrow-based lowgrade lymphomas. • PBML should be distinguished from other aggressive lymphomas which can primarily involve the bone marrow such as Burkitt lymphoma, lymphoblastic lymphoma, blastoid mantle cell lymphoma, and intravascular large B-cell lymphoma. • PET imaging is useful for monitoring lymphoma activity in the bone marrow.

show abstract

Early complete response of primary bone marrow B‐cell lymphoma treated with rituximab‐based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement

Abstract: Evaluation of early response by flow cytometry and immunogloblin heavy chain assessments against primary bone marrow B‐cell lymphoma could be valuable for predicting treatment outcome.

Cited by 2 publications

References 8 publications

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes

Contact Info

Product

Resources

About